Clinical trials: Type II Diabetic Patients With Nephropathy
Diabetic Foot, Type 2 Diabetes Mellitus With Established Diabetic Nephropathy
The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region
Objectives: Preventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions.
- Trial name
- NCT01299246
- Testing
- Michigan Neuropathy Screening Instrument
- Where
- Taiwan
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Type 2 DM /Diabetic Nephropathy
CRP to Serum Albumin Ratio in Type 2 DM é Diabetic Nephropathy
we aimed to compare C-reactive protein to serum albumin ( CAR) level of the T2DM patients with DN to those T2DM without DN
- Trial name
- NCT05681286
- Volunteers
- 70 people
- Sponsor
- Assiut University
End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria
Clinical Observation of Renal Function Reactivation Following a GRAS-Based Protocol in Patients With Chronic Kidney Disease and Long-Term Renal Arrest.
This observational study documents the impact of a specific oral protocol (based on FDA-GRAS ingredients) on patients with Stage 5 Chronic Kidney Disease (CKD).
- Conditions
- End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Stage 5
- Trial name
- NCT07555327
- Testing
- CSR-CKD Oral Protocol
- Where
- Algeria
- Volunteers
- 8 people
- Sponsor
- Amar h Zireg
Diabetic Kidney Disease
IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
To explore the efficacy of Ivabradine for the treatment of microalbuminuria in patients with type 2 diabetes and coronary heart disease.
- Trial name
- BENCH (NCT03105219)
- Testing
- Ivabradine
- Where
- China
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Diabetic Nephropathy
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
1. To evaluate expression levels of circANKRD36 in the development and progression of DN. 2. To investigate correlation between expression levels of circANKRD36 and stages of DN. 3.
- Trial name
- NCT05061459
- Testing
- circANKRD36 as a new biomarker
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Kidney Disease
Prevalence of Renal Insufficiency in Patients With Type 2 Diabetes
the prevalence of renal insufficiency in patients with type 2 diabetes (T2D) visiting a large diabetes care center in Southern India.
- Trial name
- CKD (NCT07818434)
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Trial name
- NCT07866235
- Testing
- Dapagliflozin, Empagliflozin (EMPA)
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital